Apimeds Pharmaceuticals US EBIT

As of the most recent data (June 2026), APUS shows a EBIT of $-27M. That compares with $-3.6M in the prior-year period — down 664.2% year over year. That is below the sector sector average of $2.6T. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, APUS's EBIT is now $-27M (was $-3.6M) — a 664.2% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Apimeds Pharmaceuticals US is outperforming or lagging.

The its sector sector average EBIT is about $2.6T. Apimeds Pharmaceuticals US is at $-27M, which is lower that average. That is roughly 100.0% below the sector mean. Use the comparison chart on this page to see how APUS stacks up against individual peers as well.

Tracking APUS's ebit over time shows whether Apimeds Pharmaceuticals US is scaling, shrinking, or reshaping that part of the business. The current reading is $-27M That compares with $-3.6M in the prior-year period — down 664.2% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this ebit page, Stockcircle has Apimeds Pharmaceuticals US's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect EBIT (currently $-27M) with ownership activity and broader fundamentals.